[HTML][HTML] The Role of cMET in Gastric Cancer—A Review of the Literature
F Van Herpe, E Van Cutsem - Cancers, 2023 - mdpi.com
Simple Summary cMET is a proto-oncogene that has been extensively studied in gastric
cancer. Gastric cancer (GC) is a heterogenous disease with varied histology and molecular …
cancer. Gastric cancer (GC) is a heterogenous disease with varied histology and molecular …
[HTML][HTML] Consensus recommendations to optimize testing for new targetable alterations in non-small cell lung cancer
DN Ionescu, TL Stockley, S Banerji, C Couture… - Current …, 2022 - mdpi.com
Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis
and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient …
and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient …
Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies
Brain metastases are a common occurrence in both non-small cell and small cell lung
cancer with the potential to affect quality of life and prognosis. Due to concerns about the …
cancer with the potential to affect quality of life and prognosis. Due to concerns about the …
Phase I study evaluating glesatinib (MGCD265), an inhibitor of MET and AXL, in patients with non-small cell lung cancer and other advanced solid tumors
C Kollmannsberger, H Hurwitz, L Bazhenova, BC Cho… - Targeted …, 2023 - Springer
Background Heightened signaling by mesenchymal epithelial transition factor (MET) is
implicated in tumorigenesis. Glesatinib is an investigational, oral inhibitor of MET and AXL …
implicated in tumorigenesis. Glesatinib is an investigational, oral inhibitor of MET and AXL …
[HTML][HTML] NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease
A Michelotti, M de Scordilli, E Bertoli… - International Journal of …, 2022 - mdpi.com
Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
M Filipska, R Rosell - Molecular Oncology, 2021 - Wiley Online Library
Over the past decade, substantial developments have been made in the detection of
circulating tumor DNA (ctDNA)—cell‐free DNA (cfDNA) fragments released into the …
circulating tumor DNA (ctDNA)—cell‐free DNA (cfDNA) fragments released into the …
Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
MET receptor has emerged as a druggable target across several human cancers. Agents
targeting MET and its ligand hepatocyte growth factor (HGF) including small molecules such …
targeting MET and its ligand hepatocyte growth factor (HGF) including small molecules such …
[HTML][HTML] Landscape of savolitinib development for the treatment of non-small cell lung cancer with MET alteration—A narrative review
X Zhu, Y Lu, S Lu - Cancers, 2022 - mdpi.com
Simple Summary In this article, we outline updates on the clinical development of savolitinib,
a novel, reversible c-MET kinase inhibitor conditionally approved in China for treatment of …
a novel, reversible c-MET kinase inhibitor conditionally approved in China for treatment of …
[HTML][HTML] rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Efficient predictive biomarkers are needed for immune checkpoint inhibitor (ICI)-based
immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of …
immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of …
[HTML][HTML] Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
Abstract Background This Phase 1b/2 study evaluated tepotinib, a highly selective MET
inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular …
inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular …